




(86) **Date de dépôt PCT/PCT Filing Date:** 2012/06/05
 (87) **Date publication PCT/PCT Publication Date:** 2012/12/13
 (45) **Date de délivrance/Issue Date:** 2017/02/14
 (85) **Entrée phase nationale/National Entry:** 2013/11/27
 (86) **N° demande PCT/PCT Application No.:** US 2012/040945
 (87) **N° publication PCT/PCT Publication No.:** 2012/170442
 (30) **Priorité/Priority:** 2011/06/06 (US61/493,534)

(51) **Cl.Int./Int.Cl. C07D 213/81** (2006.01),
A61K 31/137 (2006.01), **A61K 31/44** (2006.01),
C07C 211/27 (2006.01)
 (72) **Inventeurs/Inventors:**
 SHALWITZ, ROBERT, US;
 GARDNER, JOSEPH H., US;
 JANUSZ, JOHN M., US
 (73) **Propriétaire/Owner:**
 AKEBIA THERAPEUTICS INC., US
 (74) **Agent:** BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) **Titre : COMPOSES ET COMPOSITIONS POUR LA STABILISATION DU FACTEUR 2 ALPHA INDUCTIBLE PAR L'HYPOXIE
 COMME PROCEDE DE TRAITEMENT DU CANCER**
 (54) **Title: COMPOUNDS AND COMPOSITIONS FOR STABILIZING HYPOXIA INDUCIBLE FACTOR-2 ALPHA AS A METHOD FOR
 TREATING CANCER**



(57) **Abrégé/Abstract:**

Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino} acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2a) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino} acetic acid and/or a prodrug thereof which can be used to treat cancer. For example, disclosed herein are compounds of the Formula (I) and

(57) Abrégé(suite)/Abstract(continued):

pharmaceutically acceptable salts thereof, compositions comprising such compounds or salts thereof, medicaments comprising such compounds or salts thereof as well as uses of such compounds or salts thereof, compositions and medicaments: (see Formula I).